Progenity Inc. (PROG): Price and Financial Metrics


Progenity Inc. (PROG): $0.88

-0.03 (-3.47%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add PROG to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

PROG POWR Grades


  • PROG scores best on the Growth dimension, with a Growth rank ahead of 87.71% of US stocks.
  • The strongest trend for PROG is in Growth, which has been heading up over the past 179 days.
  • PROG's current lowest rank is in the Stability metric (where it is better than 1.36% of US stocks).

PROG Stock Summary

  • PROG's price/sales ratio is 183.09; that's higher than the P/S ratio of 98.56% of US stocks.
  • Revenue growth over the past 12 months for Progenity Inc comes in at -98.32%, a number that bests only 0.8% of the US stocks we're tracking.
  • In terms of volatility of its share price, PROG is more volatile than 95.79% of stocks we're observing.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Progenity Inc are WISA, ACAD, PGEN, TMDX, and GPRO.
  • To check out Progenity Inc's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001580063.

PROG Valuation Summary

  • PROG's price/earnings ratio is -0.3; this is 100.82% lower than that of the median Healthcare stock.
  • PROG's price/sales ratio has moved down 3 over the prior 15 months.
  • PROG's price/earnings ratio has moved up 2.3 over the prior 15 months.

Below are key valuation metrics over time for PROG.

Stock Date P/S P/B P/E EV/EBIT
PROG 2021-08-31 1.1 -0.5 -0.3 -0.7
PROG 2021-08-30 1.0 -0.5 -0.3 -0.7
PROG 2021-08-27 0.9 -0.4 -0.3 -0.7
PROG 2021-08-26 0.9 -0.4 -0.3 -0.7
PROG 2021-08-25 1.0 -0.5 -0.3 -0.7
PROG 2021-08-24 1.0 -0.5 -0.3 -0.7

PROG's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • PROG has a Quality Grade of D, ranking ahead of 11.47% of graded US stocks.
  • PROG's asset turnover comes in at 0.499 -- ranking 52nd of 81 Healthcare stocks.
  • 500 - Internal server error

The table below shows PROG's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.499 -0.031 -2.008
2021-03-31 0.557 -0.086 -2.222
2020-12-31 0.520 -0.257 -2.891

PROG Price Target

For more insight on analysts targets of PROG, see our PROG price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $7.00 Average Broker Recommendation 1.62 (Moderate Buy)

PROG Stock Price Chart Interactive Chart >

Price chart for PROG

PROG Price/Volume Stats

Current price $0.88 52-week high $6.20
Prev. close $0.92 52-week low $0.66
Day low $0.84 Volume 2,779,600
Day high $0.92 Avg. volume 8,589,605
50-day MA $1.17 Dividend yield N/A
200-day MA $1.85 Market Cap 162.92M

Progenity Inc. (PROG) Company Bio


Progenity, Inc. engages in the provision of molecular and specialized diagnostic tests to clinicians. Its products include Preparent Carrier Test, Innatal Prenatal Screen, Riscover Hereditary Cancer, and Resura Prenatal Test. The company was founded by Paul W. Hawran and Harry Stylli in 2010 and is headquartered in San Diego, CA.


PROG Latest News Stream


Event/Time News Detail
Loading, please wait...

PROG Latest Social Stream


Loading social stream, please wait...

View Full PROG Social Stream

Latest PROG News From Around the Web

Below are the latest news stories about Progenity Inc that investors may wish to consider to help them evaluate PROG as an investment opportunity.

Progenity Shares Two Poster Presentations on Treatment of Gastrointestinal Disorders at ECCO’22

Patient data establishes key correlations for therapeutic exposure in tissue and alternative inflammatory pathways, supporting the hypotheses of targeted therapeutic delivery and potential combination therapy for ulcerative colitisSAN DIEGO, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today shared two poster presentations that were presented during the 17th Congre

Yahoo | February 22, 2022

Progenity (PROG) Receives a Buy from H.C. Wainwright

E….

Catie Powers on TipRanks | February 16, 2022

Progenity Shares Oral Presentation on Treatment of Gastrointestinal Disorders at 34th Belgian Week of Gastroenterology

Dr. Bram Verstockt presented key patient data establishing correlation between drug levels in colon and clinical outcomesSAN DIEGO, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today shared an oral presentation that was delivered by Dr. Bram Verstockt during the 34th edition of the Belgian Week of Gastroenterology on February 9, 2022. During the oral presentation t

Yahoo | February 16, 2022

10 Stocks to Buy That Could Make You a Millionaire in 2022

After this past year, it's going to be hard to find stocks to buy to make you a millionaire in 2022.

Will Ashworth on InvestorPlace | January 26, 2022

Progenity Strengthens Intellectual Property for Single-Molecule Detection Technology with Additional Patent

SAN DIEGO, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced the award of another new patent related to its single-molecule detection assay platform under development. The USPTO has issued U.S. Patent No. 11,230,731 entitled, “Methods, Systems, and Compositions for Counting Nucleic Acid Molecules.” The issued claims are directed to detecting a labeled target molecule on a solid support. “We have added another important patent t

Yahoo | January 25, 2022

Read More 'PROG' Stories Here

PROG Price Returns

1-mo N/A
3-mo -24.14%
6-mo -57.89%
1-year -75.28%
3-year N/A
5-year N/A
YTD -57.89%
2021 -60.64%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6017 seconds.